Stock A003220 DAEWON PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Daewon Pharmaceutical Co., Ltd.

Equities

A003220

KR7003220001

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
14,660 KRW 0.00% Intraday chart for Daewon Pharmaceutical Co., Ltd. -1.87% -6.39%
03-14 Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd. CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 495.58 for the 2024 fiscal year.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DAEWON PHARMACEUTICAL CO., LTD. Stock Daewon Pharmaceutical Co., Ltd.
-6.39% 229M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.21% 238B
B+
NOVARTIS AG Stock Novartis AG
+7.09% 204B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.73% 203B
A+
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
C+
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. A003220 Stock
  4. Ratings Daewon Pharmaceutical Co., Ltd.